Avalon GloboCare Corp (NASDAQ:AVCO) said that an article featuring its QTY protein code technology was published in Chemical Reviews, the official journal of the American Chemical Society.
The publication, titled “Protein Design: From the Aspect of Water Solubility and Stability,” discusses the innovative QTY protein design code, which Avalon co-designed, as a novel platform to generate water-soluble proteins for a wide spectrum of biomedical applications.
The “QTY Code” breakthrough technology can turn water-insoluble transmembrane receptor proteins into water-soluble proteins, enabling their potential use in many clinical applications, including drug development.
Avalon initially licensed the technology from the Massachusetts Institute of Technology (MIT) and has advanced the platform through a sponsored research agreement with the university, the company said.
The Chemical Reviews piece provides a comprehensive review of the QTY protein code design platform. The QTY code design approach may have the potential to facilitate the development of important drug modalities; the creation of water-soluble proteins from insoluble proteins; the evolution of computational methods for rational drug design; the development of novel therapeutic targets for pharmaceutical and cellular medicines; and the production of other important biomedical applications.
Essentially, proteins are molecular machines inside of cells that perform the majority of essential biological functions but need to maintain their correct 3-dimensional structure. Many well-known human disorders are related to the misfolding of proteins that results in their poor solubility, stability, and function.
“We are excited to have the technology we developed together with MIT’s Dr. Zhang featured in this publication,” Avalon CEO David Jin said in a statement. “Over the past 70 years, there has been rapid advancement in the understanding of how biology works at the molecular level. Our QTY protein design code extends this knowledge, enabling an even more precise understanding and manipulation of protein structures and function.”
He continued, “Not only does the QTY code contribute significantly to the knowledge base of an important class of proteins, but we believe it also provides new pathways for further investigation and subsequent applications that were previously unattainable.”
Prior to the article’s publication, Avalon had licensed patents from MIT related to the use of QTY solubilized membrane proteins to be used as decoy receptors in therapeutics. Subsequently, the company said it has subsequently filed additional patent applications jointly with MIT and plans to apply for more patents with the university related to the QTY protein design technologies.
“As the QTY code method evolves, we expect the construction of new functional proteins will become increasingly easier,” Jin added. “Potential applications for these new designs include: (i) novel therapeutics which utilize functional equivalents of native cellular receptors; (ii) integrated vehicles for drug delivery and personalized medicine; (iii) biomimetic sensing platforms with high specificity and diagnostic precision; (iv) biocompatible human-electronic interfaces with molecular level integrations; and (v) functional supramolecular nanomaterials with hyperstability.”
Avalon GloboCare is a clinical-stage CellTech bio-developer advancing innovative immune effector cell therapy and exosome technology.
Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com
Follow him on Twitter @andrew_kessel
